Australian Operations
Include All CSL Behring Country Sites


Human C1 esterase inhibitor, powder for injection

BERINERT® is funded for patients with Type I and Type II Hereditary Angioedema. For further details on funding please go to the National Blood Authority website. To obtain a Berinert order form please contact CSL Behring Customer Service on 1800 063 892 or by emailing them on customer service.
Berinert® is a highly purified, freeze-dried C1 esterase inhibitor concentrate derived from human plasma. C1 esterase inhibitor is the primary control protein that regulates vascular permeability.

Berinert is manufactured by CSL Behring and distributed within Australia by CSL Behring (Australia).

Administration of Berinert to patients with C1 esterase inhibitor deficiency replaces the missing or malfunctioning protein in patients to relieve symptoms of hereditary angioedema (HAE). 

Berinert is indicated for the treatment of acute attacks in patients with hereditary angioedema (HAE). 

Berinert is supplied as a freeze-dried powder which is dissolved with Water for Injections and then injected into a vein. Each product package consists of one carton containing a single-use vial of Berinert and one 10 mL vial of Water for Injection, and a second carton containing one Mix2Vial™ filter transfer set, a disposable 10 mL syringe, an infusion set, two alcohol swabs and a plaster (adhesive bandage). The Mix2Vial™ filter transfer set is used to transfer the Water for Injections into the Berinert vial. 

Information on how to prepare Berinert using the Mix2Vial

Berinert is available only with a doctor’s prescription. 


Who is this information for?
This information is relevant in Australia and is intended for healthcare professionals and people who have been prescribed this product.

Consumer Medicine Information
The Consumer Medicine Information is a leaflet written for people who have been prescribed Berinert, and contains information about the medicine including:
  • What Berinert is used for
  • How Berinert works 
  • How Berinert is given
  • Side effects 
  • Further Information

Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by CSL for you if you are a:
  1. qualified healthcare professional; or
  2. consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
PDF icon BERINERT® PI 0.177MB 

® Registered Trademark of CSL Limited Group of Companies 
™ Trademark of West Pharmaceutical Services, Inc. or a subsidiary thereof